Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.43.EBIT: As of FY2026 Q1, the actual value is USD -2.448 M.<h4>Overall Financial Performance</h4>Quantum Cyber N.V. reported a net loss of - $5,081,982 for the three months ended March 31, 2026, which is a 2% increase compared to - $5,002,891 for the same period in 2025. The total comprehensive loss for the three months ended March 31, 2026, was - $5,117,078, up from - $4,839,042 in the prior year. As of March 31, 2026, the company had an accumulated deficit of approximately - $110.0 million and a net working capital deficit of approximately - $3.5 million. Total assets were $7,717,957 as of March 31, 2026, an increase from $5,327,396 as of December 31, 2025.<h4>Continuing Operations (Pancreatic Cancer Screening)</h4><ul><li>Revenue: Revenue remained $0 for both the three months ended March 31, 2026, and March 31, 2025.</li><li>Operating Expenses: Sales and marketing expenses decreased by 76% to $281,903 in 2026 from $1,160,575 in 2025. Research and development expenses decreased by 33% to $59,300 in 2026 from $88,748 in 2025. General and administrative expenses increased by 42% to $2,121,840 in 2026 from $1,496,202 in 2025. Total operating expenses decreased by 10% to $2,463,043 in 2026 from $2,745,525 in 2025.</li><li>Loss from Operations: Loss from operations decreased by 10% to - $2,463,043 in 2026 from - $2,745,525 in 2025.</li><li>Cash Flow: Cash used in operating activities was - $2,707,993 in 2026, an improvement from - $3,942,073 in 2025. Cash used in investing activities increased to - $650,658 in 2026 from - $198,042 in 2025. Cash provided by financing activities significantly increased to $7,267,225 in 2026 from cash used of - $356,958 in 2025. Cash at the end of the period for continuing operations was $4,450,193 as of March 31, 2026.</li></ul><h4>Discontinued Operations (Colorectal Cancer Screening)</h4><ul><li>Revenue: Total revenue increased by 12% to $170,105 for the three months ended March 31, 2026, from $152,405 in 2025.</li><li>Cost of Revenue and Gross Profit: Cost of revenue increased by 37% to $63,951 in 2026 from $46,745 in 2025. Gross profit increased by 1% to $106,154, but gross margins decreased from 69% to 62%.</li><li>Operating Expenses: Sales and marketing expenses increased to $393,275 in 2026 from $176,400 in 2025. Research and development expenses decreased by $420,278 to $1,152,082 in 2026 from $1,624,797 in 2025. General and administrative expenses increased to $589,717 in 2026 from $478,638 in 2025. An impairment loss on fixed assets of $538,393 was recorded in 2026.</li><li>Loss from Discontinued Operation: Loss from discontinued operations was - $2,596,387 in 2026, compared to - $2,235,434 in 2025.</li><li>Assets and Liabilities Held for Sale: Assets held for sale were $1,888,410 as of March 31, 2026, down from $3,045,627 as of December 31, 2025. Liabilities held for sale were $2,088,532 as of March 31, 2026, down from $3,828,240 as of December 31, 2025. These assets and liabilities are expected to be settled by mid-2026.</li><li>Cash Flow: Cash used in operating activities was - $1,842,893 in 2026, an improvement from - $2,740,972 in 2025. Cash used in investing activities increased to - $350,658 in 2026 from - $198,042 in 2025. Cash provided by financing activities decreased to $2,353,534 in 2026 from $2,806,493 in 2025. Cash at the end of the period for discontinued operations was $302,773 as of March 31, 2026.</li></ul><h4>Strategic Summary and Outlook</h4>Quantum Cyber N.V. is undergoing a strategic shift, exiting its colorectal cancer screening business to focus on pancreatic cancer screening products and exploring new business opportunities in the post-quantum cyber field. Key actions include the sale of ColoAlert and Next Gen product lines’ intellectual property in March and April 2026, respectively, and presenting clinical results for its pancreatic screening product line at major conferences in April and May 2026. The company has also entered into a perpetual, exclusive worldwide license agreement for cyber technology, committing $5 million in cash and issuing 20 million shares. Quantum Cyber N.V. acknowledges substantial doubt about its ability to continue as a going concern, planning to meet future cash requirements through current cash, a recently completed $6 million preferred stock offering, and potential future debt and/or equity financings.

Quantum Cyber NV | 10-Q: FY2026 Q1 Revenue: USD 0